University of Texas Southwestern Medical Center, Dallas, TX 75390. Edited by Clay M. ..... â¡Genomic sequences reported by George et al. (21). §N1376D is a ...
Myasthenic syndrome caused by mutation of the SCN4A sodium channel Akira Tsujino*†, Chantal Maertens†‡, Kinji Ohno*, Xin-Ming Shen*, Taku Fukuda*, C. Michael Harper*, Stephen C. Cannon§¶, and Andrew G. Engel* *Department of Neurology and Neuromuscular Research Laboratory and Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905; ‡Department of Neurology, Harvard Medical School, Boston, MA 02114; and §Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390 Edited by Clay M. Armstrong, University of Pennsylvania School of Medicine, Philadelphia, PA, and approved April 23, 2003 (received for review January 16, 2003)
I
n normal neuromuscular transmission, activation of acetylcholine receptors (AChRs) gives rise to an endplate potential (EPP) that activates voltage-dependent sodium channels (Nav1.4). A high concentration of AChRs on crests of the synaptic folds (1) and of Nav1.4 in the depth of the folds (2, 3) ensures that excitation is propagated beyond the endplate (EP) (4, 5). The safety margin of neuromuscular transmission is a function of the difference between the depolarization caused by the EPP and the depolarization required to activate Nav1.4. All congenital or acquired defects of neuromuscular transmission identified to date have been traced to one or more factors that render the EPP subthreshold for activating Nav1.4 (6, 7). We here describe a novel congenital myasthenic syndrome in which EPPs of normal amplitude fail to activate Nav1.4, and trace the cause of the disorder to a mutation in SCN4A that markedly enhances fast-inactivation of Nav1.4. Materials and Methods EP Studies. Intercostal muscle specimens were obtained from the patient and control subjects without muscle disease undergoing thoracic surgery. All human studies were in accord with the guidelines of the Institutional Review Board of the Mayo Clinic. Measurement of number of AChRs per EP with 125I-labeled ␣-bungarotoxin and localization of AChR and acetylcholinesterase at the EP were by described methods (8). Peroxidaselabeled ␣-bungarotoxin was used for the electron microscopy (EM) localization of AChR (9). The ␣ subunit of Nav1 sodium channels was immunolocalized in muscle with a polyclonal pan-sodium channel antibody (Alamone Labs, Jerusalem). EPs were localized for EM by established methods (10). Miniature EPP (MEPP) and EPP recordings and estimates of the number of transmitter quanta released by nerve impulse were carried out as described (8). Patch-clamp recordings from the EP AChRs were performed as described (11). www.pnas.org兾cgi兾doi兾10.1073兾pnas.1230273100
Sequencing Procedures. PCR-amplified fragments of SCN4A were cleared of unincorporated dNTPs and primers by using shrimp alkaline phosphatase (Amersham Biosciences兾United States Biochemical) and exonuclease I (Amersham Biosciences兾 United States Biochemical) and incubated at 37°C for 15 min. The enzymes were then inactivated at 80°C for 15 min (12). Plasmids were purified by the QIAprep Spin Miniprep kit (Qiagen). PCR products and plasmids were sequenced with an ABI377 DNA sequencer (Applied Biosystems) using fluorescently labeled dideoxy terminators. Mutation Analysis. DNA was isolated from muscle and blood as
described (13). To sequence all 24 exons with their flanking noncoding regions of SCN4A, we synthesized 21 pairs of PCR primers based on the genomic sequence of SCN4A (GenBank accession no. AC005803) and directly sequenced the PCR products. We used allele-specific PCR to screen 400 normal alleles for the identified mutations. CHAT, the gene encoding choline acetyltransferase, was sequenced as described (14). Because DNA from the patient’s father was not available for genetic analysis, we examined the allelic distribution of S246L and V1442E by cloning a cDNA fragment and by haplotype analysis. For cDNA cloning, we used the long-distance reverse transcription method (15) to amplify a 4-kb cDNA fragment. mRNA was isolated from the patient’s muscle by using the MicroFastTrack mRNA isolation kit (Invitrogen). We synthesized first-strand cDNA by using oligo(dT) primer with Superscript II (Invitrogen) in the presence of 170 mM trehalose (Fluka) and 766 mM sorbitol (Fluka). We performed nested touchdown RT-PCR with KlenTaq LA (CLONTECH) to amplify a cDNA fragment spanning positions 536–4388, where position ⫹1 represents the translational start site. We then cloned the RT-PCR product by using the TOPO TA Cloning System (Invitrogen) and sequenced five clones that carried the expected insert. For haplotype analysis, we analyzed four polymorphisms in intron 22 (IVS22 ⫹ 103C兾A, IVS22 ⫹ 240T兾C, IVS22 ⫹ 268C兾T, and IVS22–242ins18) by direct sequencing. We also examined (CT)n dinucleotide repeat in intron 22 and (CT)n(CA)n dinucleotide repeats in intron 23 (16) by the GeneScan Analysis System (Applied Biosystems). To locate V1442E on the identified haplotypes, we PCR-amplified and This paper was submitted directly (Track II) to the PNAS office. Abbreviations: AChR, acetylcholine receptor; CHAT, gene encoding choline acetyltransferase; CMAP, compound muscle action potential; CMS, congenital myasthenic syndrome; EP, endplate; EPP, EP potential; MEPP, miniature EPP; SCN4A, gene encoding the adult muscle sodium channel, Nav1.4. Data deposition: The human SCN4A cDNA sequence reported in this paper has been deposited in the GenBank database (accession no. AY212253). †A.T.
and C.M. contributed equally to this work.
¶To
whom correspondence should be addressed. E-mail: steve.cannon@utsouthwestern. edu.
PNAS 兩 June 10, 2003 兩 vol. 100 兩 no. 12 兩 7377–7382
PHYSIOLOGY
In a myasthenic syndrome associated with fatigable generalized weakness and recurrent attacks of respiratory and bulbar paralysis since birth, nerve stimulation at physiologic rates rapidly decremented the compound muscle action potential. Intercostal muscle studies revealed no abnormality of the resting membrane potential, evoked quantal release, synaptic potentials, acetylcholine receptor channel kinetics, or endplate ultrastructure, but endplate potentials depolarizing the resting potential to ⴚ40 mV failed to excite action potentials. Pursuing this clue, we sequenced SCN4A encoding the skeletal muscle sodium channel (Nav1.4) and detected two heteroallelic mutations involving conserved residues not present in 400 normal alleles: S246L in the S4兾S5 cytoplasmic linker in domain I, and V1442E in the S3兾S4 extracellular linker in domain IV. The genetically engineered V1442E-Na channel expressed in HEK cells shows marked enhancement of fast inactivation close to the resting potential, and enhanced use-dependent inactivation on high-frequency stimulation; S246L is likely a benign polymorphism. The V1442E mutation in SCN4A defines a novel disease mechanism and a novel phenotype with myasthenic features.
Table 1. Discordant nucleotides between our SCN4A clone and published sequences Nucleotide*
Codon
28–30
10
31–33
11
742–744
248
1111–1113
371
1675–1677
559
2608–2610
870
3451–3453
1151
3454–3456
1152
4126–4128
1376§
5530–5532
—¶
Our clone
M81758†
L04216–L04236‡
GTG Val CCT Pro AAA Lys GAG Glu AAC Asn GCG Ala AAC Asn GCC Ala AAC Asn CCC
GCT Ala CGT Arg AAG Lys AAG Lys GAC Asp — — — — — — GAC Asp CCCC
— — — — — — CAG Gln — — GGC Gly AAG Lys CCC Pro GAC Asp CCCC
Our clone has the same sequence as GenBank accession nos. L01962– L01983, NT㛭010783, and AC005803. Discordant nucleotides and codons are underlined. Em dashes indicate identity with our clone. *Position ⫹1 represent the first nucleotide of translational initiation codon. †cDNA sequence reported by George et al. (19). ‡Genomic sequences reported by George et al. (21). §N1376D is a known polymorphism (20). ¶Located in the 3⬘ noncoding region.
cloned a 2-kb genomic fragment spanning exons 22–24 from the patient’s DNA, and sequenced 12 clones. cDNA Cloning of Human SCN4A. We amplified the human SCN4A
cDNA from the fetal skeletal muscle cDNA (Marathon-Ready cDNA, CLONTECH) by nested RT-PCR. We introduced the Kozak consensus sequence (5⬘-GCCGCCACC-3⬘) into the nested RT-PCR primer before the translational initiation site (17). The RT-PCR product was cloned into a pGEM-T vector (Promega), digested with EcoRI, excised from a gel, and then transferred to a cytomegalovirus (CMV)-based expression vector, pRBG4 (18). The insert corresponds to nucleotides 78–5631 of the published SCN4A cDNA sequence (19) (GenBank accession no. M81758), where the coding region is from nucleotide 78 to nucleotide 5588. To confirm that there are no artifacts in our clone, we compared our sequence with the published SCN4A sequences. Our clone has the same coding sequence as GenBank accession nos. L01962–L01983 (20), NT㛭010783 (the National Center for Biotechnology Information Annotation Project), and AC005803 (the Human Genome Project), whereas M81758 (7) and L04216–L04236 (21) carry seven and six discordant nucleotides predicting five and five discordant amino acids, respectively (Table 1). Among these discordant amino acids, N1376D is a known polymorphism (20). We also sequenced four control human alleles and all alleles carried the same sequence as our clone. Therefore, our clone likely represents the consensus sequence of human SCN4A. The S246L and V1442E missense mutations were introduced into pRBG4-SCN4A by using the QuikChange site-directed mutagenesis kit (Stratagene). Absence of unwanted artifacts was confirmed by sequencing the entire insert. Wild-type and mutant SCN4A clones were prepared for expression studies with the HiSpeed Plasmid Maxi Kit (Qiagen). 7378 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.1230273100
Whole-Cell Recording. Sodium currents were recorded from human embryonic kidney (HEK) cells transiently transfected with wild-type or mutant pRBG4-SCN4A, the accessory 1 subunit (pGW-SCN1B), and a CD8 expression marker as described (22). The pipette (internal) solution contained 90 mM CsF, 35 mM NaC1, 10 mM EGTA, 10 mM Hepes, 1 mM MgC12, 5 mM Na2ATP, and 5 mM Na2-phosphocreatine (pH 7.4 by NaOH). The bath contained 140 mM NaC1, 4 mM KC1, 10 mM Hepes, 5 mM glucose, 1 mM MgC12, and 2 mM CaC12 (pH 7.4 by NaOH). Recordings were made at room temperature (21–23°C).
Results Clinical Data. A 20-year-old normokalemic woman had abrupt
attacks of respiratory and bulbar paralysis since birth lasting 3–30 min recurring one to three times per month. Since infancy, she has been on an apnea monitor and received ventilatory support during apneic attacks. She had delayed motor development, was always easily fatigued, and had droopy eyelids. At age 20, she had eyelid ptosis, limited ocular ductions, and facial, trunkal, and limb muscle weakness worsened by activity; she could walk less than half a block and could elevate her arms to the horizontal for only 20 sec. She had a high-arched palate, adduction deformity of the knees and ankles, and increased lumbar lordosis. She was mentally retarded; her brain MRI revealed mild cerebral atrophy that was attributed to previous episodes of cerebral anoxia. Tests for anti-AChR antibodies were negative. The patient’s mother and sister were asymptomatic. No clinical data or DNA were available from the patient’s father. Nerve Stimulation Studies. Trains of stimuli at 2, 10, and 50 Hz
were used to elicit compound muscle action potentials (CMAPs) from small hand muscles. In the patient, 10-Hz stimulation for 5 min, or 50-Hz stimulation for 2 sec, decremented the CMAP by ⬇85%. A 2-Hz stimulation did not decrement the CMAP in rested muscle but elicited a 50% decrement after a conditioning train of 10-Hz stimuli for 1 min (Fig. 1 A–D). In a control, 10-Hz stimulation for 5 min reduced the CMAP only by ⬇35%, 50-Hz stimulation for 2 sec caused pseudofacilitation (increased amplitude with proportionate decrease in area), and 2-Hz stimulation elicited no decrement before or after 10-Hz stimulation for 5 min (Fig. 1 E–H). Thus, sustained high-frequency stimulation, or low-frequency stimulation after a conditioning train of high-frequency stimulation, reduced the safety margin of neuromuscular transmission in the patient. Muscle Histology. None of the intercostal muscle fibers harbored
vacuoles of the type often observed in periodic paralysis muscle specimens. Type 1 fibers had a smaller mean diameter than type 2 fibers. The random distribution of the histochemical fiber types was maintained.
EP Studies. The number of AChR per EP, determined with
125I-labeled ␣-bungarotoxin, was normal. The muscle fiber membrane potential was similar to that recorded from control muscle fibers (Table 2). EPPs of the order of 40 mV depolarizing the membrane potential to ⫺40 mV or more failed to trigger action potentials and were recorded in the absence of D-tubocurarine (Fig. 2A). The MEPP amplitude and quantal content of the EPP were normal. Ten-hertz stimulation for 5 min decreased the EPP only by ⬇13% (Fig. 2B) (normal ⬍30%, ref. 23). Patch-clamp recordings from three EPs revealed AChR channels opening to a normal conductance of ⬇60 pS and a channel opening burst of normal duration (Table 2). Immunolocalization of sodium channels with an anti-pan sodium channel antibody showed similar surface membrane and similarly enhanced synaptic expression at patient and control muscle fibers (Fig. 3). EM examination of 63 regions of 34 EPs
Tsujino et al.
Fig. 2. (A) EPP recorded from patient intercostal muscle depolarizes the resting potential from ⫺73 to ⫺43 mV but fails to elicit an action potential. (B) The EPP elicited by 10-Hz nerve stimulation over 5 min first facilitates and then decreases by ⫺13% from baseline. Individual symbols represent means of 100 EPPs recorded over 10-sec intervals.
Fig. 1. Hypothenar CMAP in patient (A–D) and thenar CMAP in control (E–H) evoked by stimulation at 2, 10, and 50 Hz. Ten-hertz stimulation for 5 min (C) or 50-Hz stimulation for 2 sec (D) decrement the patient CMAP by ⬇85%; 2-Hz stimulation for 2 sec has no effect on the patient CMAP unless it is preceded by a 10-Hz conditioning train (A and B). Control CMAP decrements slightly after 10-Hz stimulation (G), pseudofacilitates after 50-Hz stimulation (H), and is unaffected by 2-Hz stimulation before or after a 10-Hz conditioning train (E and F). Numbers in D and H indicate nth CMAPs elicited during 50-Hz stimulation.
revealed normal nerve terminals and well developed junctional folds at all EPs. A single postsynaptic region was denuded of its nerve terminal. The density and distribution of AChR on the crests of the junctional folds, determined with peroxidaselabeled ␣-bungarotoxin, was normal. Table 2. Endplate studies Controls
Patient
To summarize, nerve stimulation studies combined with in vitro analysis of neuromuscular transmission indicate that physiologic rates of stimulation compromise the safety margin of neuromuscular transmission. The effect on the safety margin cannot be accounted for by a decreased amplitude of the EPP at rest or after protracted 10-Hz stimulation, by a deficiency or kinetic abnormality of AChR, by an alteration of the EP geometry, or by a paucity of junctional or extrajunctional sodium channels. Mutation Analysis. Because some features of the patient’s illness
resembled the CMS caused by mutations in CHAT (14, 24), we first sequenced CHAT but observed no mutations. That EPPs depolarizing the muscle fiber membrane potential to ⫺40 mV failed to activate action potentials prompted us to search for a mutation SCN4A that encodes Nav1.4. We therefore directly sequenced the 24 exons with their flaking noncoding regions of SCN4A and identified two missense mutations. The first mutation is a C-to-T transition at nucleotide 737, where the position ⫹1 represents the translational start site, predicting S246L in the cytoplasmic link between the S4 and S5 segments of domain I. The second mutation is a T-to-A transversion at nucleotide 4325, predicting V1442E in the extracellular link between the S3 and S4 segments of domain IV (Fig. 4). Neither S246L nor V1442E was observed in 400 normal alleles. Both S246 and V1442 are
[125I]␣-bgt
Values indicate mean ⫾ SEM. Measurements were made at 30°C for MEPPs and EPPs and at 22°C for single-channel recordings. Numbers in parentheses indicate number of subjects for [125I]␣-bgt binding sites兾EP and number of fibers or EPs for other measurements. *Measured with 10 –15 M⍀ glass microelectrodes. †Corrected for a resting membrane potential of ⫺80 mV and nonlinear summation. ‡Corrected for a resting membrane potential of ⫺80 mV, nonlinear summation, and non-Poisson release. §Corrected for resting membrane potential of ⫺80 mV and for a fiber diameter of 50 m. ¶ACh, 1 M; pipette potential, 80 mV; bandwidth, 5.8 kHz.
Tsujino et al.
Fig. 3. Sodium channel (A and C) and AChE (B and D) localization in patient (A and B) and control (C and D) muscle fibers. EPs are identified by localization of AChE in the same sections. Sodium channel expression is similar at the surface membrane and is similarly enhanced at the EP in patient and control fibers. (Magnification, ⫻370.) PNAS 兩 June 10, 2003 兩 vol. 100 兩 no. 12 兩 7379
PHYSIOLOGY
binding 12.82 ⫾ 0.79 E6 (13) 11.51 E6 sites兾EP Resting membrane ⫺72.5 ⫾ 0.78 (75) ⫺75.5 ⫾ 1.4 (13 fibers) potential, mV* ND 42.6 ⫾ 5.05 (12) EPP amplitude, mV† Quantal release at 1 Hz‡ 31 ⫾ 1 (190) 36 ⫾ 4.3 (12) MEPP amplitude, mV§ 1.00 ⫾ 0.025 (165) 1.17 ⫾ 0.08 (9) Single-channel opening bursts¶ 2, ms 0.12 ⫾ 0.012 (32) 0.067 ⫾ 0.0078 (3) Area 0.16 ⫾ 0.014 0.16 ⫾ 0.025 2, ms 3.04 ⫾ 0.175 (34) 2.91 ⫾ 0.32 (3) Area 0.85 ⫾ 0.015 0.84 ⫾ 0.024
Table 3. Nav1.4 gating behavior Channel
Fig. 4. Scheme of skeletal muscle sodium channel Nav1.4 encoded by SCN4A and the identified mutations.
conserved across Nav1.4 channels of different species. S246L is conserved across the ␣ subunits of human sodium channels Nav1.1 to Nav1.5, Nav1.8, and Nav1.9; V1442 is similarly conserved except for the ␣ subunit of Nav1.5. The patient also carries a previously unreported G524D polymorphism, detected in 2 of 24 in controls. Family analysis indicates that the asymptomatic mother and sister are heterozygous for S246L. Because the father’s DNA was not available for genetic analysis, we examined the allelic dis-
Fig. 5. Gating behavior of heterologously expressed sodium channels. (A) Channel availability (left) after a 300-msec prepulse was left-shifted for mutant channels, whereas activation (right) was unchanged. Parameter values for Boltzmann fits are listed in Table 3. (B) The kinetics of fast-inactivation were left-shifted for mutant channels (n ⫽ 7–12). Inactivation kinetics were measured as: recovery at ⫺135 to ⫺80 mV after 30-msec prepulse to ⫺10 mV, closed-state entry with progressively longer prepulses over a range from ⫺60 to ⫺45 mV, or as the current decay rate for test depolarization ⱖ ⫺45 mV. For V1442E, the recovery兾prepulse voltages for the inactivation protocols were shifted by ⫺30 mV, to detect Na current in the presence of the large left-shift of inactivation. (Inset) Superposition of amplitude-normalized responses for a depolarization to ⫺30 mV from a holding potential of ⫺120 mV. 7380 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.1230273100
Wild type
S246L
V1442E
Activation V1/2, mV ⫺29.0 ⫾ 1.2 (7) ⫺29.7 ⫾ 2.0 (12) ⫺28.8 ⫾ 2.2 (8) k, mV 5.3 ⫾ 0.3 (7) 6.3 ⫾ 0.5 (12) 6.9 ⫾ 0.3 (8) Fast-inactivation V1/2, mV ⫺66.9 ⫾ 1.2 (11) ⫺74.2 ⫾ 0.8 (17) ⫺100.1 ⫾ 0.8 (11) k, mV 4.8 ⫾ 0.1 (11) 4.2 ⫾ 0.1 (17) 5.0 ⫾ 0.1 (11) Slow-inactivation V1/2, MV ⫺52.9 ⫾ 2.4 (5) ⫺72.5 ⫾ 3.0 (8) ⫺49.9 ⫾ 1.8 (4) k, mV 12.3 ⫾ 1.0 (5) 10.8 ⫾ 0.5 (8) 14.5 ⫾ 0.5 (4) Io 0.17 ⫾ 0.03 (5) 0.32 ⫾ 0.04 (8) 0.11 ⫾ 0.02 (4) Voltage dependence of relative current was fit by a Boltzmann function except for slow-inactivation, which was fit with a Boltzmann plus a constant: I ⫽ Io ⫹ (1 ⫺ Io)兾(1 ⫹ exp((V ⫺ V1/2)兾k)). Numbers in parentheses indicate number of cells.
tribution of S246L and V1442E by cloning a cDNA fragment and by haplotype analysis. Cloning of a 4-kb RT-PCR product spanning S246L and V1442E from the patient’s muscle revealed that the mutations are heteroallelic. We also found a G524D polymorphism in the allele harboring V1442E. Haplotype analysis using three single-nucleotide polymorphisms, one insertion polymorphism, and two polymorphic dinucleotide repeats in introns 22 and 23 confirmed the heteroallelic distribution of the two mutations. Heterologous Expression Studies. Our wild-type construct and both mutants expressed at levels comparable to the previously published cDNA for Nav1.4 (19) as judged by current density. Channel activation by depolarization was not altered by either mutation (Fig. 5A, right). The voltage dependence of fast inactivation produced by a 300-msec conditioning pulse was markedly left-shifted by ⫺33 mV for the V1442E mutant, whereas the S246L mutant had a milder shift of ⫺7 mV (Fig. 5A and Table 3). This shift in steady-state behavior was accompanied by a commensurate left shift in the voltage-dependence for the kinetics of fast inactivation (Fig. 5B). The limiting value for the time constant of current decay at positive test potentials reflects the microscopic inactivation rate from the open state (25) and was not affected by either mutation. Neither mutation disrupted the completeness of fast inactivation, as revealed by the lack of an increased persistent Na current at the end of a 10-msec depolarization (Fig. 5B Inset). Sodium channel mutations found in periodic paralysis often disrupt slow inactivation (26). We assessed slow inactivation by applying a 30-sec conditioning pulse, followed by recovery at ⫺120 mV for 20 msec to remove fast inactivation and a test depolarization to ⫺10 mV. The V1442E mutation did not affect slow inactivation, whereas a mixed effect was observed for S247L: enhancement of slow inactivation by a ⫺20 mV leftward shift, and impaired maximal extent of slow inactivation at depolarized potentials (Fig. 6 and Table 3). The response to a 50-Hz train of 3-msec pulses was measured to assess whether use-dependent Na channel inactivation might contribute to the abnormal decremental CMAP response observed in the patient’s muscle at high-frequency stimulation. The normalized peak current amplitude had a precipitous drop of 30% during the first few pulses for the V1442E mutant, whereas wild-type and S246L channels showed only a 5% decrease (Fig. 7). The rapid decrement is caused by trapping of V1442E channels in the fast-inactivated state because recovery at ⫺100 mV is slowed 3-fold for this mutant (Fig. 5B). Conversely, the lack of a difference between wild-type and S246L channels after 200 pulses suggests that neither the alterations in slow inactivaTsujino et al.
diminished expression of AChE or AChR, a kinetic defect in AChR, or alteration of EP geometry, were excluded by the EP studies. The present phenotype differs from that of periodic paralyses associated with hitherto identified mutations of SCN4A. The onset is neonatal, the disorder is normokalemic, the attacks selectively involve bulbar and respiratory muscles, physiologic rates of stimulation decrement the CMAP abnormally, and the muscle fiber membrane potential is normal when action potential generation fails. Periodic paralyses stemming from mutations in SCN4A present later in life, the attacks typically spare cranial, bulbar, and respiratory muscles, the serum potassium level increases or declines during attacks in most cases, mild exercise for brief periods does not decrement the CMAP, and the resting membrane potential of the muscle fiber is decreased when action potential generation fails (27, 28).
tion nor the milder shift in fast inactivation for S246L is sufficient to produce abnormal use dependence during 50-Hz stimulation. Discussion The Clinical Features Herald a Myasthenic Phenotype. The patient’s fatigable weakness involving lid-elevator, external ocular, and facial as well as limb and trunkal muscles and the decremental response of the CMAP on repetitive stimulation were consistent with a myasthenic phenotype. The patient’s apneic attacks and the requirement for a conditioning train of stimuli at 10 Hz to elicit a decremental response at 2-Hz stimulation closely mimic features of a presynaptic CMS caused by mutations in CHAT (14, 24). In the present disorder, however, the stimulation-dependent decrement of the CMAP is not owing to impaired resynthesis of acetylcholine and concomitant abnormal decrease of the EPP, but stems from a defect in Nav1.4. Other factors that compromise neuromuscular transmission in previously recognized congenital myasthenic syndromes, e.g., decrease of evoked quantal release,
Fig. 7. Relative Na current during a 50-Hz train of 3-msec depolarizations to ⫺10 mV from a holding potential of ⫺100 mV. Every 20th response is shown after the break at the 10th pulse.
Tsujino et al.
Mechanisms Accounting for Reduced Availability of Functional NaV1.4.
The loss-of-function defect in this case of congenital myasthenic syndrome is attributable to the left shift in the voltage dependence of fast inactivation. Depolarization induces outward movement of all four S4 voltage sensors, but fast inactivation is only linked to S4 movements of domains III and IV (30). The enhanced inactivation of V1442E can be explained by a mutation-induced bias in the voltage-dependent motion of IV兾S4 toward the outward conformation. In contrast, mutations at the arginine residues of IV兾S4 that cause myotonia and slow the rate of inactivation (31) are presumably because of an effect on the rate of a conformational change rather than on inducing bias. At the normal resting potential of ⫺90 mV, 98% of wild-type channels remain available, whereas for V1442E channels the availability is only 13% (Fig. 5A). The defect is compounded by enhanced cumulative use-dependent inactivation (Fig. 7), which further reduces V1442E channel availability and may explain the abnormal CMAP decrement observed at high-frequency stimulation (Fig. 1). The bias of having the majority of wild-type channels non-inactivated at ⫺90 mV may have evolved to ensure rapid recovery and thereby minimize use dependence at physiological rates of discharge. S246L also shifts the availability curve to the left (Fig. 5A), but this ⫺7 mV shift alone is clinically silent (unaffected mother and sister), compared with the ⫺10 PNAS 兩 June 10, 2003 兩 vol. 100 兩 no. 12 兩 7381
PHYSIOLOGY
Fig. 6. Slow inactivation after a 30-sec conditioning pulse, and an intervening recovery at ⫺120 mV for 20 msec to remove fast inactivation, was less complete for S246L and shifted toward more negative potentials (see Table 3 for fitted parameters).
Relation to Other Na Channel Diseases. Mutations in the coding region of voltage-gated sodium channels are known to be a cause of epilepsy and cardiac arrhythmia, in addition to skeletal muscle disorders with myotonia, periodic paralysis, and now congenital myasthenia features (28). All of these disorders are inherited as dominant traits, and the mutant channels are functional, albeit with altered gating behavior. Most of these mutations produce gain-of-function defects wherein impairment of inactivation, or less commonly enhanced activation, results in excessive inward Na current. At the cellular level, the aberrant current may induce autonomous firing (myotonia), delayed repolarization (cardiac long QT), or prolonged depolarization and block of action potentials (periodic paralysis). Each of these defects occurs because of the tendency for the excessive activity mutant channels to depolarize the cell. In contrast, loss-of-function defects consistently occur in only a subset of periodic paralysis: those with features of hypokalemic periodic paralysis (HypoPP) due to mutations in Nav1.4 (28, 29). As expected for a loss-of-function, action potentials in affected muscle have smaller overshoots and slower rates of rise. The defect described herein is a more extreme example, with complete failure of action potential initiation by a normal EPP (Fig. 2). Commensurate with this more pronounced defect in excitability, the leftward (hyperpolarized) shift for inactivation was much greater for V1442E (⫺30 mV, Fig. 5A) than the ⫺10 mV shift observed for R672 mutants in HypoPP.
mV shift purported to cause HypoPP for the R672G兾H mutations (28). The inheritance pattern for this case of congenital myasthenic syndrome cannot be unambiguously established. The more severe V1442E mutation may be dominant, but this cannot be proven because this mutation was observed only in combination with the heteroallelic S246L mutation. The S246L mutation alone was clinically silent and therefore either represents a rare polymorphism with detectable biophysical changes, but no clinical or EMG phenotype, or a recessive mutation. Despite this uncertainty, this report clearly establishes a congenital myasthenic syndrome as a new allelic disorder to be grouped with the myotonias and periodic paralyses previously attributed to mutations in Nav1.4. Our findings also have therapeutic implica-
tions: After the defect in Nav1.4 was established in the patient, therapy with pyridostigmine (60–120 mg three times daily), which increases the number of AChRs activated by each quantum, improved the patient’s endurance; additional therapy with acetazolamide (250 mg twice daily), which is known to mitigate periodic paralysis due to Nav1.4 mutations, prevented further attacks of respiratory and bulbar weakness. Moreover, this study demonstrates that a reduced margin of safety for neuromuscular transmission may occur in the setting of a normal EPP.
1. Salpeter, M. M. (1987) in Vertebrate Neuromuscular Junctions: General Morphology, Molecular Organization, and Functional Consequences, ed. Salpeter, M. M. (Liss, New York), pp. 1–54. 2. Flucher, B. E. & Daniels, M. P. (1989) Neuron 3, 163–175. 3. Ruff, R. L. (1996) Acta Physiol. Scand. 156, 159–168. 4. Martin, A. R. (1994) Proc. R. Soc. London B 258, 321–326. 5. Wood, S. J. & Slater, C. P. (2001) Prog. Neurobiol. 64, 393–429. 6. Harper, C. M. (1999) in Electrodiagnosis of Endplate Disease, ed. Engel, A. G. (Oxford Univ. Press, New York), pp. 65–84. 7. Engel, A. G., Ohno, K. & Sine, S. M. (2002) Mol. Neurobiol. 26, 347–367. 8. Engel, A. G., Nagel, A., Walls, T. J., Harper, C. M. & Waisburg, H. A. (1993) Muscle Nerve 16, 1284–1292. 9. Engel, A. G., Lindstrom, J. M., Lambert, E. H. & Lennon, V. A. (1977) Neurology 27, 307–315. 10. Engel, A. G. (1994) in Myology, eds. Engel, A. G. & Franzini-Armstrong, C. (McGraw–Hill, New York), 2nd Ed., pp. 1018–1045. 11. Milone, M., Hutchinson, D. O. & Engel, A. G. (1994) Muscle Nerve 17, 1364–1369. 12. Dorit, R. L., Ohara, O., Wang, C. B. C., Kim, J. B. & Blackshaw, S. (2001) in Current Protocols in Molecular Biology, eds. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seiman, J. G., Smith, J. A. & Struhl, K. (Wiley, New York), pp. 15.2. 13. Ohno, K., Hutchinson, D. O., Milone, M., Brengman, J. M., Bouzat, C., Sine, S. M. & Engel, A. G. (1995) Proc. Natl. Acad. Sci. USA 92, 758–762. 14. Ohno, K., Tsujino, A., Brengman, J. M., Harper, C. M., Bajzer, Z., Udd, B., Beyring, R., Robb, S., Kirkham, F. J. & Engel, A. G. (2001) Proc. Natl. Acad. Sci. USA 98, 2017–2022. 15. Carninci, P., Shiraki, T., Mizuno, Y., Muramatsu, M. & Hayashizaki, Y. (2002) BioTechniques 32, 984–985.
16. McClatchey, A. I., Trofatter, J., McKanna-Yasek, D., Easkind, W., Bird, T., Pericak-Vance, M., Gilchrist, J., Arahata, K., Radosavljevic, D. & Worthen, H. G. (1992) Am. J. Hum. Genet. 50, 896–901. 17. Kozak, M. (1987) Nucleic Acids Res. 15, 8125–8148. 18. Ohno, K., Wang, H.-L., Milone, M., Bren, N., Brengman, J. M., Nakano, S., Quiram, P., Pruitt, J. N., Sine, S. M. & Engel, A. G. (1996) Neuron 17, 157–170. 19. George, A. L., Jr., Komisarof, J., Kallen, R. G. & Barchi, R. L. (1992) Ann. Neurol. 31, 131–137. 20. McLatchey, A. I., Lin, C. S., Wang, J., Hoffman, E. P., Rojas, C. & Gusella, J. F. (1992) Hum. Mol. Genet. 1, 521–527. 21. George, A. L., Jr., Iyer, G. S., Kleinfeld, R., Kallen, R. G. & Barchi, R. L. (1993) Genomics 15, 598–606. 22. Hayward, L. J., Brown, R. H. & Cannon, S. C. (1996) J. Gen. Physiol. 107, 559–576. 23. Engel, A. G. & Lambert, E. H. (1987) Electroencephalogr. Clin. Neurophysiol. Suppl. 39, 91–102. 24. Mora, M., Lambert, E. H. & Engel, A. G. (1987) Neurology 37, 206–214. 25. Aldrich, R. W., Corey, D. P. & Stevens, C. F. (1983) Nature 306, 436–441. 26. Cannon, S. C. (2002) Neuromuscul. Disord. 12, 533–543. 27. Engel, A. G., Potter, C. S. & Rosevear, J. W. (1965) Am. J. Med. 38, 626–640. 28. Lehmann-Horn, F. & Jurkat-Rott, K. (1999) Physiol. Rev. 79, 1317–1372. 29. Struyk, A. F., Scoggan, K. A., Bulman, D. E. & Cannon, S. C. (2000) J. Neurosci. 20, 8610–8617. 30. Cha, A., Ruben, P. C., George, A. L., Jr., Fujimoto, E. & Bezanilla, F. (1999) Neuron 22, 73–87. 31. Yang, N., Ji, S., Zhou, M., Ptacek, L. J., Barchi, R. L., Horn, R. & George, A. L., Jr. (1994) Proc. Natl. Acad. Sci. USA 91, 12785–12789.
7382 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.1230273100
We thank Dr. M. Takagishi and Dr. G. A. Ristow for patient referral. This work was supported by National Institutes of Health Grants NS6277 (to A.G.E.) and AR42703 (to S.C.C.), and a Muscular Dystrophy Association grant (to A.G.E.). C.M. is an Aspirant of the Fonds voor Wetenschappelijk Onderzoek–Vlaanderen.
Tsujino et al.
